Hurun India Rich List 2026 edition · 1 director
- #1,608 Anil Kumar Karusala & family ₹1,200 Cr
Market Cap
₹2,134 Cr
SAIPARENT · NSE
Share Price
₹483.00
-0.88% today
Revenue
₹381 Cr
FY 2025-26 · +133.6% YoY
EBITDA
₹38.77 Cr
Margin 10.2%
Net Profit
₹14.27 Cr
FY 2025-26 · -1.0% YoY
P/E (TTM)
103.7x
P/B 4.4x
ROE
4.9%
ROCE 4.8%
Debt / Equity
0.96
Interest cover 84.4x
About Sai Parenteral's Limited
Data last updated:
Sai Parenteral's Limited is a public limited company based in Hyderabad, Telangana, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 12 January 2001 and has been in existence for over 25 years.
Its director Anil Kumar Karusala and family are #1,608 on the Hurun India Rich List 2026.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24231TG2001PLC036043. Its GSTIN is 36AAFCS3053H1ZF (Telangana). The company holds 2 GST registrations, of which 1 is active. Its shares are listed on BSE: 544742 and NSE: SAIPARENT.
The company has an authorised share capital of ₹25.76 Cr and a paid-up capital of ₹18.45 Cr. It was formerly known as Sai Parenteral'S Private Limited. It is led by directors including Anil Kumar Karusala (Managing Director) and Vijitha Gorrepati (Whole-Time Director).
Its last annual general meeting (AGM) was held on 27 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Hyderabad, Telangana.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹381 Cr, a growth of 133.6% compared to the previous year. For the same year it recorded a net profit of ₹14.27 Cr (net margin 3.7%) and EBITDA of ₹38.77 Cr (EBITDA margin 10.2%). The net worth stands at ₹490.77 Cr (up 423.9% YoY). Total assets are valued at ₹1,094.51 Cr (up 475.4% YoY).
The company has about 235 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: SAI Parenterals. As per MCA filings, the company has open charges of ₹213.36 Cr and satisfied charges of ₹121.89 Cr on record. Court records list 12 cases involving the company, including 6 filed by the company and 5 filed against it; 9 cases are pending. The company has 31 deals on record (19 secondary share transfers, 8 funding rounds, 3 market trades), with disclosed funding of ₹165.67 Cr; the latest was in April 2026. Its 10 peer companies in the Pharma industry (Formulations) are compared by revenue, 5 larger and 5 smaller; the largest is DWD Pharmaceuticals Limited with revenue of ₹166.47 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website saiparenterals.com.
Company Details of Sai Parenteral's Limited
CIN U24231TG2001PLC036043
Registration Number 036043
Incorporation Date 12 January 2001
ROC Hyderabad
Listing Status Listed (BSE: 544742, NSE: SAIPARENT)
Company Status Active
Date of Last AGM 27 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
CIN History of Sai Parenteral's Limited
Sai Parenteral's has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is U24231TG2001PLC036043, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24231TG2001PLC036043 | Current |
| U24231TG2001PTC036043 | Previous |
| U24231AP2001PTC036043 | Previous |
Key People
Anil Kumar Karusala Managing Director Vijitha Gorrepati Whole-Time Director Kalidindi Venkateswara Raju Director Recognitions & Rankings of Sai Parenteral's
Contact Details
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered AddressPlot No 39 5th Floor, Lavanya Arcade Jayabheri Enclave Gachibowli, Hyderabad, Telangana, India – 500032
- IndustryPharma, Drug Formulation & Development
Comprehensive company report
Sai Parenteral's Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Associated Brands with Sai Parenteral's Limited
Sai Parenteral's operates one associated brand: SAI Parenterals. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Parenteral products including sterile injections and pharmaceutical services are provided. | saiparenterals.com |
Business Activity of Sai Parenteral's Limited
The main business activity of Sai Parenteral's is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Premium access
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Sai Parenteral's Limited FY 2025-26 filings available
Sai Parenteral's Limited reported revenue of ₹381 Cr (up 133.6% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹381 Cr
+133.6% YoY
EBITDA
₹38.77 Cr
-1.5% YoY
Profit After Tax
₹14.27 Cr
-1.0% YoY
Net Worth
₹491 Cr
+423.9% YoY
Total Assets
₹1,095 Cr
+475.4% YoY
Total Debt
₹469 Cr
+398.9% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 381 | 163 | 154 | 96.80 |
| Revenue growth | +133.6% | +6.1% | +58.8% | - |
| EBITDA | 38.77 | 39.38 | 31.69 | 18.53 |
| EBITDA margin | +10.2% | +24.1% | +20.6% | +19.1% |
| Profit before tax | 11.93 | 19.94 | 12.57 | 7.24 |
| Net profit | 14.27 | 14.42 | 8.43 | 4.36 |
| Net profit margin | +3.8% | +8.8% | +5.5% | +4.5% |
| EPS (₹) | 3.23 | 5.43 | 6.35 | 6.12 |
| Balance sheet | ||||
| Total assets | 1,095 | 190 | 195 | 100 |
| Net worth | 491 | 93.67 | 74.55 | 31.49 |
| Total debt | 469 | 93.96 | 119 | 68.55 |
| Cash & bank | 417 | 2.09 | 4.38 | 0.17 |
| Net working capital | 492 | 118 | 115 | 48.21 |
| Cash flow | ||||
| Cash from operations | 93.05 | 33.15 | (29.76) | (12.80) |
| Cash from investing | (274) | 0.44 | (46.32) | (19.03) |
| Cash from financing | 596 | (35.88) | 78.57 | 23.98 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| Revenue | 179 | 198 | 96.15 | 53.53 | 33.39 |
| Revenue growth (YoY) | +435.1% | - | - | - | - |
| Other income | 3.74 | 2.88 | 3.13 | 1.34 | 1.17 |
| EBITDA | 23.52 | 26.09 | (3.56) | 11.42 | 4.74 |
| EBITDA margin | +13.2% | +13.2% | -3.7% | +21.3% | +14.2% |
| Depreciation | 8.11 | 8.18 | 5.79 | 1.44 | 1.45 |
| Interest | 9.36 | 8.40 | 5.41 | 2.17 | 2.46 |
| Profit before tax | 9.79 | 12.39 | (11.63) | 9.15 | 2.00 |
| Tax | 1.86 | (0.76) | (4.96) | 2.81 | 0.59 |
| Net profit | 7.93 | 13.15 | (6.67) | 6.34 | 1.41 |
| EPS (₹) | 1.79 | 4.02 | (2.22) | 0.00 | 0.11 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 166 | 127 | 114 | 96.80 |
| Revenue growth | +31.1% | +11.1% | +17.7% | - |
| EBITDA | 28.48 | 26.86 | 21.48 | 17.67 |
| EBITDA margin | +17.2% | +21.2% | +18.9% | +18.3% |
| Profit before tax | 18.77 | 14.38 | 10.22 | 7.28 |
| Net profit | 16.78 | 10.29 | 7.20 | 4.56 |
| Net profit margin | +10.1% | +8.1% | +6.3% | +4.7% |
| EPS (₹) | 3.80 | 3.86 | 5.41 | 6.43 |
| Balance sheet | ||||
| Total assets | 622 | 163 | 149 | 100 |
| Net worth | 487 | 91.22 | 78.08 | 31.48 |
| Total debt | 133 | 71.79 | 71.15 | 68.55 |
| Cash & bank | 410 | 1.10 | 1.38 | 1.91 |
| Net working capital | 405 | 78.90 | 75.78 | 52.00 |
| Cash flow | ||||
| Cash from operations | 112 | 18.68 | (4.43) | (20.83) |
| Cash from investing | (136) | (13.16) | (31.97) | (17.26) |
| Cash from financing | 433 | (5.81) | 35.88 | 30.23 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 |
|---|---|---|---|---|
| Revenue | 52.78 | 56.79 | 38.48 | 19.20 |
| Revenue growth (YoY) | +174.9% | - | - | - |
| Other income | 3.41 | 0.12 | 0.75 | 1.24 |
| Total expenses | 39.43 | 43.57 | 34.50 | 16.17 |
| EBITDA | 13.35 | 13.22 | 3.98 | 3.03 |
| EBITDA margin | +25.3% | +23.3% | +10.3% | +15.8% |
| Depreciation | 1.36 | 1.53 | 1.60 | 1.32 |
| Interest | 3.57 | 3.42 | 2.12 | 1.76 |
| Profit before tax | 11.83 | 8.39 | 1.01 | 1.19 |
| Tax | 2.95 | (1.55) | 0.64 | 0.36 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 20 Oct 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| Revenue | 179 | 198 | 96.15 | 53.53 | 33.39 |
| Revenue growth (YoY) | +435.1% | - | - | - | - |
| Other income | 3.74 | 2.88 | 3.13 | 1.34 | 1.17 |
| EBITDA | 23.52 | 26.09 | (3.56) | 11.42 | 4.74 |
| EBITDA margin | +13.2% | +13.2% | -3.7% | +21.3% | +14.2% |
| Depreciation | 8.11 | 8.18 | 5.79 | 1.44 | 1.45 |
| Interest | 9.36 | 8.40 | 5.41 | 2.17 | 2.46 |
| Profit before tax | 9.79 | 12.39 | (11.63) | 9.15 | 2.00 |
| Tax | 1.86 | (0.76) | (4.96) | 2.81 | 0.59 |
| Net profit | 7.93 | 13.15 | (6.67) | 6.34 | 1.41 |
| EPS (₹) | 1.79 | 4.02 | (2.22) | 0.00 | 0.11 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Revenue | 381 | 163 | 154 | 96.80 |
| Revenue growth | +133.6% | +6.1% | +58.8% | - |
| Other income | 8.52 | 0.67 | 1.42 | 0.23 |
| Total expenses | 342 | 124 | 122 | 78.27 |
| Employee cost | 29.28 | 13.09 | 12.64 | 8.92 |
| EBITDA | 38.77 | 39.38 | 31.69 | 18.53 |
| EBITDA margin | +10.2% | +24.1% | +20.6% | +19.1% |
| Depreciation | 16.85 | 8.20 | 9.42 | 5.79 |
| Interest | 18.51 | 11.91 | 11.12 | 5.73 |
| Profit before tax | 11.93 | 19.94 | 12.57 | 7.24 |
| Tax | (2.34) | 5.49 | 4.14 | 2.88 |
| Net profit | 14.27 | 14.42 | 8.43 | 4.36 |
| Net profit margin | +3.8% | +8.8% | +5.5% | +4.5% |
| EPS (₹) | 3.23 | 5.43 | 6.35 | 6.12 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Equity & liabilities | ||||
| Share capital | 22.09 | 13.31 | 13.25 | 7.15 |
| Reserves & surplus | 469 | 80.36 | 61.30 | 24.34 |
| Shareholders' funds (net worth) | 491 | 93.67 | 74.55 | 31.49 |
| Minority interest | 4.35 | 2.11 | 1.86 | 0.00 |
| Secured loans | 284 | 87.36 | 114 | 68.00 |
| Unsecured loans | 185 | 6.60 | 4.77 | 0.55 |
| Total debt | 469 | 93.96 | 119 | 68.55 |
| Total liabilities | 1,095 | 190 | 195 | 100 |
| Assets | ||||
| Gross block | 432 | 79.50 | 99.33 | 55.08 |
| Net block | 364 | 53.20 | 70.01 | 44.47 |
| Capital work in progress | 212 | 0.50 | 0.00 | 1.60 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 172 | 51.08 | 37.21 | 13.19 |
| Sundry debtors | 181 | 127 | 127 | 61.21 |
| Cash & bank balances | 417 | 2.09 | 4.38 | 0.17 |
| Loans & advances | 52.17 | 20.19 | 18.69 | 7.37 |
| Total current assets | 822 | 200 | 187 | 81.94 |
| Total current liabilities | 330 | 82.16 | 72.71 | 33.73 |
| Net working capital | 492 | 118 | 115 | 48.21 |
| Total assets | 1,095 | 190 | 195 | 100 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Opening cash | 2.09 | 4.38 | 1.90 | 9.75 |
| Net cash from operating activities | 93.05 | 33.15 | (29.76) | (12.80) |
| Net cash from investing activities | (274) | 0.44 | (46.32) | (19.03) |
| Net cash from financing activities | 596 | (35.88) | 78.57 | 23.98 |
| Net change in cash | 415 | (2.30) | 2.48 | (7.85) |
| Closing cash | 417 | 2.09 | 4.38 | 0.17 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Growth | ||||
| Sales growth | +133.6% | +6.1% | +58.8% | - |
| EBITDA growth | -1.6% | +24.3% | +71.0% | - |
| PBT growth | -40.2% | +58.6% | +73.6% | +9997.0% |
| Net income growth | -1.0% | +71.1% | +93.4% | - |
| Revenue CAGR (3Y) | +57.9% | - | - | - |
| EBITDA CAGR (3Y) | +27.9% | - | - | - |
| Profitability & leverage | ||||
| Net income margin | +3.8% | +8.9% | +5.5% | +4.5% |
| Return on capital employed | +4.8% | +16.7% | +16.1% | +13.0% |
| Return on net worth | +4.9% | +17.2% | +15.9% | +13.9% |
| Debt / equity | 0.96 | 1.26 | 1.77 | 2.18 |
| Long-term debt / equity | 0.42 | 0.38 | 0.74 | 1.06 |
| Interest cover | 84.44 | 38.20 | 49.93 | 44.98 |
| Efficiency & per share | ||||
| Fixed asset turnover | 1.49 | 1.82 | 1.99 | 1.76 |
| Inventory turnover | 3.42 | 3.69 | 6.10 | 7.34 |
| Debtors turnover | 2.48 | 1.29 | 1.63 | 1.58 |
| EPS (₹) | 3.23 | 5.43 | 6.35 | 6.12 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 111.08 | 35.19 | 56.27 | 44.03 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 |
|---|---|---|---|---|
| Revenue | 52.78 | 56.79 | 38.48 | 19.20 |
| Revenue growth (YoY) | +174.9% | - | - | - |
| Other income | 3.41 | 0.12 | 0.75 | 1.24 |
| Total expenses | 39.43 | 43.57 | 34.50 | 16.17 |
| EBITDA | 13.35 | 13.22 | 3.98 | 3.03 |
| EBITDA margin | +25.3% | +23.3% | +10.3% | +15.8% |
| Depreciation | 1.36 | 1.53 | 1.60 | 1.32 |
| Interest | 3.57 | 3.42 | 2.12 | 1.76 |
| Profit before tax | 11.83 | 8.39 | 1.01 | 1.19 |
| Tax | 2.95 | (1.55) | 0.64 | 0.36 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Revenue | 166 | 127 | 114 | 96.80 |
| Revenue growth | +31.1% | +11.1% | +17.7% | - |
| Other income | 4.84 | 0.32 | 1.09 | 0.21 |
| Total expenses | 137 | 99.72 | 92.41 | 79.13 |
| Employee cost | 14.30 | 10.92 | 10.31 | 8.92 |
| EBITDA | 28.48 | 26.86 | 21.48 | 17.67 |
| EBITDA margin | +17.2% | +21.2% | +18.9% | +18.3% |
| Depreciation | 5.78 | 5.49 | 6.18 | 5.79 |
| Interest | 8.77 | 7.31 | 6.17 | 4.81 |
| Profit before tax | 18.77 | 14.38 | 10.22 | 7.28 |
| Tax | 1.99 | 4.09 | 3.04 | 2.67 |
| Net profit | 16.78 | 10.29 | 7.20 | 4.56 |
| Net profit margin | +10.1% | +8.1% | +6.3% | +4.7% |
| EPS (₹) | 3.80 | 3.86 | 5.41 | 6.43 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Equity & liabilities | ||||
| Share capital | 22.09 | 13.31 | 13.25 | 7.15 |
| Reserves & surplus | 465 | 77.91 | 64.83 | 24.33 |
| Shareholders' funds (net worth) | 487 | 91.22 | 78.08 | 31.48 |
| Secured loans | 0.00 | 0.00 | 69.35 | 68.00 |
| Unsecured loans | 133 | 71.79 | 1.80 | 0.55 |
| Total debt | 133 | 71.79 | 71.15 | 68.55 |
| Total liabilities | 622 | 163 | 149 | 100 |
| Assets | ||||
| Gross block | 70.78 | 62.18 | 58.17 | 55.08 |
| Net block | 42.72 | 39.90 | 41.38 | 44.47 |
| Capital work in progress | 1.09 | 0.50 | 0.00 | 1.60 |
| Investments | 158 | 28.39 | 28.39 | 0.00 |
| Inventories | 59.50 | 26.19 | 18.92 | 13.19 |
| Sundry debtors | 81.22 | 86.49 | 84.78 | 61.21 |
| Cash & bank balances | 410 | 1.10 | 1.38 | 1.91 |
| Loans & advances | 35.93 | 16.66 | 15.39 | 9.42 |
| Total current assets | 587 | 130 | 120 | 85.73 |
| Total current liabilities | 182 | 51.54 | 44.69 | 33.73 |
| Net working capital | 405 | 78.90 | 75.78 | 52.00 |
| Total assets | 622 | 163 | 149 | 100 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Opening cash | 1.10 | 1.38 | 1.91 | 9.76 |
| Net cash from operating activities | 112 | 18.68 | (4.43) | (20.83) |
| Net cash from investing activities | (136) | (13.16) | (31.97) | (17.26) |
| Net cash from financing activities | 433 | (5.81) | 35.88 | 30.23 |
| Net change in cash | 409 | (0.29) | (0.52) | (7.85) |
| Closing cash | 410 | 1.10 | 1.38 | 1.91 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Growth | ||||
| Sales growth | +31.1% | +11.1% | +17.7% | - |
| EBITDA growth | +6.0% | +25.1% | +21.6% | - |
| PBT growth | +30.5% | +40.7% | +40.4% | +9997.0% |
| Net income growth | +63.1% | +42.9% | +57.9% | - |
| Revenue CAGR (3Y) | +19.7% | - | - | - |
| EBITDA CAGR (3Y) | +17.3% | - | - | - |
| Profitability & leverage | ||||
| Net income margin | +10.1% | +8.1% | +6.3% | +4.8% |
| Return on capital employed | +7.0% | +13.9% | +13.1% | +12.1% |
| Return on net worth | +5.8% | +12.1% | +13.1% | +14.6% |
| Debt / equity | 0.35 | 0.84 | 1.28 | 2.18 |
| Long-term debt / equity | 0.09 | 0.18 | 0.40 | 0.81 |
| Interest cover | 38.63 | 34.21 | 40.33 | 40.49 |
| Efficiency & per share | ||||
| Fixed asset turnover | 2.50 | 2.10 | 2.01 | 1.76 |
| Inventory turnover | 3.87 | 5.61 | 7.09 | 7.34 |
| Debtors turnover | 1.98 | 1.48 | 1.56 | 1.58 |
| EPS (₹) | 3.80 | 3.86 | 5.41 | 6.43 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 110.23 | 34.27 | 58.94 | 44.02 |
Want more history and ratios?
You're viewing the latest exchange-filed financials for Sai Parenteral's Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
Board of Directors of Sai Parenteral's Limited
Sai Parenteral's has 6 current directors and 9 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Kalidindi Venkateswara Raju | Director | 12 Nov 2024 | 1 Years 11 Months | Current |
| Bhagyashri Dharmasa Zad Also directs: Revat Laboratories Private Limited, Ecoboard Industries Limited | Director | 01 Jan 2024 | 2 Years 9 Months | Current |
| Aruna Karusala Also directs: Revat Laboratories Private Limited | Director | 16 Aug 2016 | 10 Years 2 Months | Current |
| Anil Kumar Karusala | Managing Director | 19 Nov 2021 | 4 Years 11 Months | Current |
| Seeta Ram Anjaneyulu Gorantla | Director | 01 Jan 2024 | 2 Years 9 Months | Current |
| Vijitha Gorrepati | Whole-Time Director | 16 Aug 2016 | 10 Years 2 Months | Current |
Peer Comparison of Sai Parenteral's Limited
Sai Parenteral's Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Sai Parenteral's Limited this company | ₹381 Cr (FY 2026) | •••• | •••• | 133.6% | •••• | Hyderabad, Telangana, India |
| DWD Pharmaceuticals Limited | ₹166.47 Cr (FY 2025) | •••• | •••• | 10.0% | •••• | Mumbai, Maharashtra, India |
| S. Parikh Pharma Private Limited | ₹165.85 Cr (FY 2024) | •••• | •••• | -6.0% | •••• | Mumbai, Maharashtra, India |
| Inject Care Parenterals Private Limited | ₹165.13 Cr (FY 2025) | •••• | •••• | 13.0% | •••• | Vapi, Gujarat, India |
| Time Cap Pharma Labs Private Limited | ₹165.03 Cr (FY 2025) | •••• | •••• | 477.0% | •••• | Hyderabad, Telangana, India |
| Deedy Chemicals Pvt Ltd | ₹163.89 Cr (FY 2025) | •••• | •••• | 22.0% | •••• | Ahmedabad, Gujarat, India |
| Hufort Healthcare Private Limited | ₹163.29 Cr (FY 2023) | •••• | •••• | 4.0% | •••• | Mumbai, Maharashtra, India |
| Orbit Lifescience Private Limited | ₹162.97 Cr (FY 2025) | •••• | •••• | -15.0% | •••• | Mumbai, Maharashtra, India |
| Alencure Biotech Private Limited | ₹162.35 Cr (FY 2025) | •••• | •••• | 8.0% | •••• | Nahan, Himachal Pradesh, India |
| Plasmagen Biosciences Private Limited | ₹161.85 Cr (FY 2025) | •••• | •••• | 1558.0% | •••• | Bangalore, Karnataka, India |
| Laboratoires Griffon Private Limited | ₹161.12 Cr (FY 2024) | •••• | •••• | 8.0% | •••• | Kolkata, West Bengal, India |
Peers are the five companies nearest above and the five nearest below Sai Parenteral's by revenue in the Pharma industry (Formulations), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Sai Parenteral's Limited
Sai Parenteral's Limited is audited by R. KABRA & CO. LLP for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| R. KABRA & CO. LLP | Locked | Locked | Locked |
Premium access
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Shareholding Pattern of Sai Parenteral's Limited
Shareholding for the quarter ended Sep 2026: promoters hold 51.20%, foreign institutional investors hold 4.00%, domestic institutional investors hold 8.60% and retail and other public shareholders hold 36.30%.
Sep 2026
QUARTER
51.20% Promoters
8.60% DII (Domestic Institutional)
4.00% FII (Foreign Institutional)
36.30% Retail & Others
Promoter holding - history
Now 51.20% · Sep 2026High 51.20% · Mar 2026Low 51.20% · Mar 2026
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | |
|---|---|---|---|
| Promoters | 51.20% | 51.20% | 51.20% |
| Public | 48.80% | 48.80% | 48.80% |
Charges & Borrowings of Sai Parenteral's Limited
Open charges
₹213.36 Cr
Satisfied charges
₹121.89 Cr
Breakdown by lending institutions
Latest charge details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 17 Dec 2025 | Others | ₹38 Cr | Open |
| 11 Dec 2025 | Axis Bank Limited | ₹61 Cr | Open |
| 08 Dec 2025 | The Hongkong and Shanghai Banking Corporation Limited | ₹1.25 Cr | Open |
| 29 Aug 2025 | Others | ₹20 Cr | Open |
| 30 Oct 2024 | Others | ₹47.51 Cr | Open |
Total charge records: 39 View all charges
Deals & Funding of Sai Parenteral's Limited
Sai Parenteral's Limited has 31 deals on record (19 secondary share transfers, 8 funding rounds, 3 market trades), with disclosed funding of ₹165.67 Cr; the latest was in April 2026.
Total deals
31
Secondary share transfers
19
Funding rounds
8
Market trades
3
IPO
1
Disclosed funding
₹165.67 Cr
Deals on record (5 of 31)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2025 | Secondary share transfer | Undisclosed | Buyer: Agilis Partners LLP , an individual Seller: an individual |
| Aug 2025 | Funding round | ₹46.5 Cr | Investors: Agilis Partners LLP , Gruhas, Smartgo Prop Llp, an individual |
| Mar 2025 | Secondary share transfer | Undisclosed | Buyer: 4 individuals Seller: Magnifiq Securities Private Limited , 3 individuals |
| Feb 2024 | Funding round | ₹12.02 Cr | Investors: Vikasa India Eif I Fund, Ideas and Journeys Private Limited , 2 individuals |
| Jul 2023 | Secondary share transfer | Undisclosed | Buyer: Magnifiq Securities Private Limited Seller: an individual |
Premium access
Full deal history
All 31 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal Cases of Sai Parenteral's Limited
Sai Parenteral's Limited has 12 court cases on record: 6 filed by Sai Parenteral's, 5 filed against it, 1 where it is another party. 9 cases are pending and 3 are disposed. Status as checked between 21 Sep 2026 and 03 Oct 2026.
Total cases
12
Filed by the company
6
Filed against the company
5
Pending
9
Disposed
3
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 6 | 1 | 4 |
| District courts | 5 | 4 | 4 |
| Supreme Court | 1 | 0 | 1 |
Cases on record (5 of 12)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court for State of Telangana | Revision petition | Filed against the company by Jodas Expoim Private Limited | Pending |
| District court, South Twenty Four Parganas, West Bengal | Criminal complaint | Filed against the company by an individual | Pending |
| District court, Hyderabad CCC, Telangana | Court case (MVOP) | Filed against the company by an individual | Pending |
| District court, Hyderabad CCC, Telangana | Court case (MVOP) | Filed against the company by an individual | Pending |
| High Court of Rajasthan | Interim or miscellaneous application | Filed by the company against State of Rajasthan | Pending |
Premium access
Full case history
All 12 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Employees and EPFO Compliance at Sai Parenteral's Limited
Sai Parenteral's Limited has a workforce of 235 employees as of Apr 09, 2024.
Employee count
235
Active EPFO establishments
1
Employee growth
8.8%
Premium access
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Sai Parenteral's Limited
Sai Parenteral's Limited has 13 board changes on record since 2010: 6 appointments and 7 cessations. The latest: Kalidindi Venkateswara Raju was appointed as Director on 12 Nov 2024.
Charges
A charge with Others amounted to Rs. 38.00 Cr with Charge ID 101210350 was registered on 17 Dec 2025.
Charges
A charge with Axis Bank Limited amounted to Rs. 61.00 Cr with Charge ID 101210375 was registered on 11 Dec 2025.
Charges
A charge with The Hongkong And Shanghai Banking Corporation Limited amounted to Rs. 1.25 Cr with Charge ID 101206434 was registered on 08 Dec 2025.
Charges
A charge with Others of Rs. 20.00 Cr registered on 29 Aug 2025 with Charge ID 101149137 was modified on 03 Oct 2025.
AGM
Sai Parenteral'S Limited last Annual general meeting of members was held on 27 Sep 2025 as per latest MCA records.
Charges
A charge with Others amounted to Rs. 20.00 Cr with Charge ID 101149137 was registered on 29 Aug 2025.
Charges
A charge registered on 16 Aug 2021 via Charge ID 100470023 with Sidbi was fully satisfied on 02 Jul 2025.
Charges
A charge registered on 03 Dec 2020 via Charge ID 100393761 with Sidbi was fully satisfied on 02 Jul 2025.
Filing
Sai Parenteral'S Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad.
Charges
A charge registered on 21 Jun 2023 via Charge ID 100733480 with Others was fully satisfied on 21 Jan 2025.
Charges
A charge registered on 13 May 2022 via Charge ID 100572364 with Others was fully satisfied on 21 Jan 2025.
Charges
A charge registered on 13 May 2022 via Charge ID 100572372 with Others was fully satisfied on 21 Jan 2025.
88 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Sai Parenteral's Limited
Premium access
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Sai Parenteral's Limited
Premium access
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Sai Parenteral's Limited
Premium access
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Sai Parenteral's Limited
Sai Parenteral's has 2 GST registrations: 1 active and 1 cancelled or inactive.
Total GSTINs
2
Active
1
Cancelled / inactive
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AAFCS3053H1ZF | Telangana | Active | 01 Jul 2017 |
Premium access
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Sai Parenteral's Limited
Premium access
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Related news about Sai Parenteral's Limited
SAI Parenterals: Company Finalizes Purchase of 60% Interest in R&D Facility Prathyak Laboratories for ₹15 Crore.
Frequently Asked Questions about Sai Parenteral's Limited
Sai Parenteral's is an active public limited company based in Hyderabad, Telangana, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 12 January 2001 (25+ years old) and is registered under CIN U24231TG2001PLC036043. Listed on BSE: 544742 and NSE: SAIPARENT.
Sai Parenteral's reported revenue of ₹381 Cr for FY 2025-26 (up 133.6% YoY) based on consolidated financials.
Sai Parenteral's has 6 current directors:
- Anil Kumar Karusala - Managing Director
- Vijitha Gorrepati - Whole-Time Director
- Kalidindi Venkateswara Raju - Director
- Bhagyashri Dharmasa Zad - Director
- Aruna Karusala - Director
- Seeta Ram Anjaneyulu Gorantla - Director
The GSTIN of Sai Parenteral's is 36AAFCS3053H1ZF, registered in Telangana. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Sai Parenteral's is U24231TG2001PLC036043. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Sai Parenteral's is listed on both BSE (code: 544742) and NSE (symbol: SAIPARENT).
Sai Parenteral's has 12 court cases on record: 6 filed by the company and 5 filed against it. 9 are pending. Most are in the high courts.
Sai Parenteral's was incorporated on 12 January 2001, making it 25+ years old. It is registered with the Registrar of Companies, Hyderabad.
Sai Parenteral's has 31 deals on record (19 secondary share transfers, 8 funding rounds, 3 market trades), with disclosed funding of ₹165.67 Cr; the latest was in April 2026.
The peers of Sai Parenteral's by revenue are DWD Pharmaceuticals Limited, S. Parikh Pharma Private Limited, Inject Care Parenterals Private Limited, Time Cap Pharma Labs Private Limited, Deedy Chemicals Pvt Ltd and 5 more, all in the Pharma industry (Formulations).
Kalidindi Venkateswara Raju was appointed as Director on 12 Nov 2024. Sowjanyalakshmi Tatapudi ceased to be CFO on 31 Oct 2024. Bhagyashri Dharmasa Zad was appointed as Director on 01 Jan 2024. Sai Parenteral's has 13 board changes on record in total.